High tissue content of urokinase plasminogen activator (u-PA) is associated with high stromal expression of u-PA mRNA in poorly differentiated serous ovarian carcinoma
Open Access
- 12 December 1998
- journal article
- Published by Wiley in International Journal of Cancer
- Vol. 79 (6) , 588-595
- https://doi.org/10.1002/(sici)1097-0215(19981218)79:6<588::aid-ijc6>3.0.co;2-w
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- The urokinase-type plasminogen activator system in cancer metastasis: A reviewInternational Journal of Cancer, 1997
- The significance of urokinase-type plasminogen activator, its inhibitors, and its receptor in ascites of patients with epithelial ovarian cancerCancer, 1995
- Urokinase (uPA) and PAI-1 Predict Survival in Advanced Ovarian Cancer Patients (FIGO III) after Radical Surgery and Platinum-Based ChemotherapyGynecologic Oncology, 1994
- Plasminogen activators and plasminogen activator inhibitors in blood and tumour fluids of patients with ovarian cancerEuropean Journal Of Cancer, 1994
- Induction of c‐fos gene expression by urokinase‐type plasminogen activator in human ovarian cancer cellsFEBS Letters, 1994
- Involvement of inflammatory mediators in macrophage antitumor activityJournal of Leukocyte Biology, 1993
- Increased Cell-surface Urokinase in Advanced Ovarian CancerJapanese Journal of Cancer Research, 1993
- Interaction of urokinase‐type plasminogenactivator (u‐PA) with its cellular receptor (u‐PAR) induces phosphorylation on tyrosine of a 38 kDa proteinFEBS Letters, 1993
- Radioimmunoassay of urokinase for quantification of plasminogen activators released in ovarian tumour culturesPublished by Elsevier ,1981
- Immunological identity of urokinase and ovarian carcinoma plasminogen activator released in tissue cultureNature, 1976